眼窩萎縮症の世界市場-2023年～2030年

概要

眼窩萎縮症市場は、高齢化、技術の進歩、研究開発の進展、患者の認識と教育、規制当局の承認などの要因によって牽引されています。

小さく限局性で、境界明瞭でなく、色素の薄い窩洞病変または楔状窩洞病変が存在し、一方で網膜の他の部分は無傷である場合、眼窩萎縮症と呼ばれます。中心窩はしばしば窩と呼ばれ、神経感覚網膜にある小さなくぼみで、視力が最も高いです。黄斑の窩は中心にあり、中心視力を担っていますが、それ自体です。

数多くの黄斑、血管、遺伝、炎症、毒性、外傷性網膜疾患はすべて、眼窩萎縮症を伴う可能性があります。一般的には、加齢黄斑変性、近視性変性、血管筋、長期間の嚢胞様黄斑浮腫、黄斑ジストロフィーなどの一般的な地理的萎縮に分類されます。

また、他の網膜疾患による黄斑萎縮と呼ばれることもあります。黄斑光毒性や中心性漿液性脈絡網膜症のような一部の網膜疾患では、萎縮は一般に小さな病変として現れます。萎縮は時に窩縁部や楔状窩縁部に生じることがあります。

市場力学

研究活動の活発化が世界の眼窩萎縮症市場の成長を牽引

中心漿液性脈絡網膜症（CSC）の患者に対して、光線力学的治療（PDT）を半量投与したところ、構造的にも機能的にも有利であり、中心漿液性脈絡網膜症の患者には眼窩萎縮症が生じませんでした。慢性CSC患者57人に対し、窩洞を治療部位とする1回半量PDTを行っています。

ベースライン時および治療後の数回の診察時に、光干渉断層計スキャンと眼底自発蛍光画像を用いて、構造的改善と萎縮発生の可能性を調べた。調査によると、光干渉断層計における外境界膜と楕円帯の完全性、眼底自発蛍光における低自己蛍光が1次評価項目でした。

人口の高齢化が世界の眼窩萎縮症市場の成長を押し上げる

特に加齢黄斑変性（AMD）においては、眼窩萎縮症の発症と進行は高齢化によって大きく影響を受けます。加齢に伴い、AMDや眼窩萎縮症を発症する可能性は大幅に上昇します。50歳を超えると、AMDを発症するリスクは大幅に上昇し、そのリスクは加齢とともに上昇し続ける。これは、目の自然な老化プロセスにより、目が傷つきやすく、劣化しやすくなるためです。

細胞の変化や、網膜を含むいくつかの組織への害の蓄積は、老化現象の一部です。これは最終的に黄斑部の細胞の健康と機能性に影響を及ぼし、眼窩萎縮症を引き起こす可能性があります。

眼窩萎縮症の課題が世界の眼窩萎縮症市場の成長を妨げる

眼窩萎縮症の治療法には改善が見られるもの、眼窩萎縮症の原因となるAMDやスターガルト病などの病気は、いまだに治療法が確立されていません。このため、患者の選択肢が制限され、市場の拡大が遅れる可能性があります。抗VEGF注射は、費用がかかり、頻繁に行う必要がある治療法の一例です。特定の患者、特に医療が十分に行き届かない地域では、治療へのアクセスが制限される可能性があります。眼窩萎縮症は、AMDのような多因子にわたる複雑な疾患によって生じることが多いです。根本的な問題を解決するような、焦点を絞った薬を作るのは難しいかもしれません。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 人口の高齢化
  • 抑制要因
    • 眼窩萎縮症に伴う課題
  • 機会
    • 技術進歩
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 タイプ別

• ぶどう膜性眼窩萎縮症
• 局所性眼窩萎縮症

第10章 薬剤クラス別

• 抗VEGF療法
• 遺伝子治療
• その他

第11章 エンドユーザー別

• 眼科クリニック
• 病院
• 研究機関

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Novartis AG
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Regeneron Pharmaceuticals
• Genetech
• AbbVie
• Others

第15章 付録

Overview

The Foveal atrophy market is driven by factors such as the aging population, advances in technology, increasing research and development, patient awareness and education, and regulatory approvals.

A small, focal, poorly defined, hypopigmented foveal or juxtafoveal lesion is referred to as focal foveal atrophy when it is present but the rest of the retina is unharmed. The fovea centralis, often known as the fovea, is a tiny depression located in the neurosensory retina that has the best visual acuity. The macula's fovea, which is in the center and is responsible for central vision, is by itself.

Numerous macular, vascular, genetic, inflammatory, toxic, and traumatic retinal illnesses can all be accompanied by foveal atrophy. It is typically categorized under the general heading of geographic atrophy in people with age-related macular degeneration, myopic degeneration, angioid streaks, long-term cystoid macular edema from any source, and macular dystrophies.

It is also sometimes referred to as macular atrophy due to other retinal illnesses. In some retinal illnesses, such as macular phototoxicity and resolved central serous chorioretinopathy, atrophy typically manifests as a tiny lesion. Atrophy can occasionally develop in the foveal or juxtafoveal area.

Market Dynamics

The Increasing Research Activities are Driving the Global Foveal Atrophy Market Growth

One application of half-dose photodynamic treatment (PDT) targeting the fovea was found to be structurally and functionally advantageous for treating individuals with chronic central serous chorioretinopathy (CSC), and they did not experience foveal atrophy. A single half-dose PDT with a treatment location that included the fovea was administered to a total of 57 patients with chronic CSC.

At baseline and numerous visits after therapy, optical coherence tomography scans and fundus autofluorescence images were examined for structural improvement and potential atrophic development. According to researchers, the external limiting membrane and ellipsoid zone integrity on optical coherence tomography, as well as hypoautofluorescence on fundus autofluorescence, were the primary outcome measures.

The Aging Population Boost the Global Foveal Atrophy Market Growth

The development and progression of foveal atrophy are significantly influenced by the aging population, particularly in the context of age-related macular degeneration (AMD). With age, the likelihood of developing AMD and foveal atrophy greatly rises. Over the age of 50, there is a significant increase in the risk of having AMD, and the risk keeps rising with age. This is due to the fact that the eyes' natural aging process renders them more vulnerable to harm and deterioration.

Cellular changes and accumulative harm to several tissues, including the retina, are part of the aging process. This may eventually have an effect on the health and functionality of the cells in the macula, causing foveal atrophy.

Challenges with Foveal Atrophy are Hampering the Global Foveal Atrophy Market Growth

Although there have been improvements in the ways that foveal atrophy can be treated, illnesses like AMD or Stargardt disease, which cause foveal atrophy, still have no known cure. This may restrict patients' alternatives and slow market expansion. Anti-VEGF injections are one example of a therapy option that might be costly and may need to be administered frequently. For certain patients, especially in areas with insufficient healthcare coverage, this may limit their access to treatment. Foveal atrophy frequently results from multifactorial, complicated diseases like AMD. It can be difficult to create focused medicines that go at the root problems.

Segment Analysis

The global foveal atrophy market is segmented based on type, drug class, treatment, end-user and region.

The Pharmacological Interventions Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The pharmacological interventions segment accounted for the highest market stake accounting for approximately 41.2% of the foveal atrophy market in 2022. Pharmacological interventions, which include those that deal with disorders like age-related macular degeneration (AMD) and stargardt disease that cause foveal atrophy, refer to the use of pharmaceuticals and treatments to treat a variety of illnesses. Wet AMD, a type of AMD characterized by aberrant blood vessel formation beneath the retina, is commonly treated with anti-VEGF (vascular endothelial growth factor) medication.

These aberrant blood arteries can cause bleeding and leakage, which exacerbates foveal atrophy. Anti-VEGF medications are injected into the eye to stop the development of these vessels, lessen leaking, and stop the disease's progression. Ranibizumab, aflibercept, and bevacizumab are typical anti-VEGF medications.

Geographical Penetration

North America Holds a Dominant Position in the Global Foveal Atrophy Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. Due to longer life expectancies and the aging baby boomer generation, the United States is quickly aging. Age-related eye disorders including age-related macular degeneration (AMD), which can cause foveal atrophy, are more common as people get older.

The United States has a strong healthcare system with cutting-edge medical equipment, research centers, and therapeutic alternatives. This encourages the early recognition, evaluation, and management of disorders such as foveal atrophy.

Competitive Landscape

The major global players in the market include: Novartis AG, Regeneron Pharmaceuticals, Genetech, AbbVie among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the foveal atrophy market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. The infrastructure and healthcare systems in affected areas can be strained by conflict and war. Emergency medical demands may have taken priority over healthcare, especially the treatment of disorders like foveal atrophy that affect the eyes.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the foveal atrophy market to improve various aspects of drug development. AI-driven simulations and data analysis can hasten the development of new foveal atrophy drugs. In order to develop new therapeutics, AI systems can forecast how prospective treatments would impact retinal cells.

By Type

• Uveitic Foveal Atrophy
• Focal Foveal Atrophy

By Drug class

• Anti-VEGF Therapy
• Gene Therapy
• Others

By Treatment

• Pharmacological Interventions
• Surgical Interventions

By End-user

• Ophthalmology Clinics
• Hospitals
• Research Institutions

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Why Purchase the Report?

• To visualize the global foveal atrophy market segmentation based on the type, drug class, treatment, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of foveal atrophy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of critical products of all the major players.

The global foveal atrophy market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Treatment
• 3.4. Snippet by End-user
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Aging population
  • 4.1.2. Restraints
    • 4.1.2.1. Challenges associated with Foveal Atrophy
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.1.2. Market Attractiveness Index, By Type
• 9.2. Uveitic Foveal Atrophy*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Focal Foveal Atrophy

10. By Drug Class

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.1.2. Market Attractiveness Index, By Drug Class
• 10.2. Anti-VEGF Therapy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Gene Therapy
• 10.4. Others

11. By End-user

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 11.1.2. Market Attractiveness Index, By End-user
• 11.2. Ophthalmology Clinics*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Hospitals
• 11.4. Research Institutions

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.7.1. U.S.
    • 12.2.7.2. Canada
    • 12.2.7.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.7.1. Germany
    • 12.3.7.2. U.K.
    • 12.3.7.3. France
    • 12.3.7.4. Italy
    • 12.3.7.5. Spain
    • 12.3.7.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.7.1. Brazil
    • 12.4.7.2. Argentina
    • 12.4.7.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.7.1. China
    • 12.5.7.2. India
    • 12.5.7.3. Japan
    • 12.5.7.4. Australia
    • 12.5.7.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Novartis AG*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Regeneron Pharmaceuticals
• 14.3. Genetech
• 14.4. AbbVie
• 14.5. Others

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us